BLU - Biotech's big fall catalysts to watch out for from Evercore

Evercore ISI has set up its list of key catalysts for the rest of 2021 in the biotechnology sector - including early-stage data readouts as well as some important legal and regulatory updates ahead for particular companies. Along the way it tees up its rule of thumb on biotech catalysts: "Always best to play a basket of catalysts, especially in a bullish biotech tape. Binary events are often best avoided in a bearish biotech tape." And on upcoming Phase 2 and Phase 3 data releases, one significant binary standout is AbbVie's (NYSE:ABBV) Phase 3 duplicate trial data on Vraylar for adjunctive major depressive disorders, with primary completion coming as early as the coming week. The company has been touting that event as a value driver, but Evercore notes some intermediate risk in the event "given that placebo-controlled MDD trials are unpredictable and it's not clear if ABBV has the right

For further details see:

Biotech's big fall catalysts to watch out for, from Evercore